Filtered By:
Condition: Bleeding
Procedure: Angioplasty
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 1131 results found since Jan 2013.
Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research
Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: A systematic review and meta - analysis
CONCLUSION: Shortened DAPT signifcantly reduced the odds of major bleedings in patients undergoing complex PCI, without increasing the ischemic events or mortality. Thus, it could be considered as a safe and feasible option in such patients.PMID:36736730 | DOI:10.1016/j.hjc.2023.01.005
Source: Hellenic Journal of Cardiology - February 3, 2023 Category: Cardiology Authors: Anastasios Apostolos Dimitrios Chlorogiannis Georgios Vasilagkos Konstantinos Katsanos Konstantinos Toutouzas Adel Aminian Dimitrios Alexopoulos Periklis Davlouros Grigorios Tsigkas Source Type: research
Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study
CONCLUSIONS: This study provides first-in-human evidence that P2Y12 inhibitor monotherapy directly following PCI for NSTE-ACS is feasible, without any overt safety concerns, and highlights the need for randomised controlled trials comparing direct P2Y12 inhibitor monotherapy with the current standard of care.PMID:36734020 | DOI:10.4244/EIJ-D-22-00886
Source: EuroIntervention - February 3, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Niels M R van der Sangen Bimmer E P M Claessen I Tarik K üçük Alexander W den Hartog Jan Baan Marcel A M Beijk Ronak Delewi Tim P van de Hoef Paul Knaapen Jorrit S Lemkes Koen M Marques Alexander Nap Niels J W Verouden M Marije Vis Robbert J de Winter Source Type: research
Association between the number of academic research consortium for high bleeding risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Association between the number of academic research consortium for high bleeding risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Association between the number of academic research consortium for high bleeding risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Association between the number of Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Association between the number of academic research consortium for high bleeding risk (ARC-HBR) criteria and clinical outcomes in patients with acute coronary syndrome
CONCLUSIONS: ARC-HBR score was independently associated with an increased risk of MACE in patients with ACS after an emergent PCI. Moreover, it had a similar diagnostic ability for predicting MACE within two years compared to the CADILLAC risk score.PMID:36682715 | DOI:10.1016/j.jjcc.2023.01.003
Source: Journal of Cardiology - January 22, 2023 Category: Cardiology Authors: Hirokazu Shimono Akihiro Tokushige Daisuke Kanda Ayaka Ohno Masao Hayashi Mana Fukuyado Mitsumasa Akao Mariko Kawasoe Ryo Arikawa Hideaki Otsuji Hideto Chaen Hideki Okui Naoya Oketani Mitsuru Ohishi Source Type: research
Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes
CONCLUSIONS: Ticagrelor and prasugrel are increasingly used in patients with CCS undergoing PCI with similar 1-year efficacy and safety when compared to clopidogrel. Whether use of these agents can be beneficial in patients undergoing PCI for CCS with a high thrombotic and low bleeding risk warrants further study.PMID:36660810 | DOI:10.4244/EIJ-D-22-00654
Source: EuroIntervention - January 20, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Anoop N Koshy Gennaro Giustino Samantha Sartori Amit Hooda Yihan Feng Clayton Snyder Shabitri Dasgupta Kartik R Kumar Parasuram Krishnamoorthy-Melarcode Joseph Sweeny Sahil Khera Gregory W Serrao Raman Sharma George Dangas Annapoorna S Kini Roxana Mehran Source Type: research
